Moderate immunogenicity and excellent safety of an inactivated virus vaccine against SARS-CoV-2 in primary Sjögren’s syndrome: a prospective phase 4 controlled trial
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI